You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Recurrent multiple myeloma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Multiple Myeloma Trial in Tianjin (QLS32015)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jun 24, 2023

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Los Angeles (procedure, drug, other)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Bone Marrow Aspiration
  • +10 more
  • Los Angeles, California
    Melanie Ayala Ceja
Jul 10, 2023

Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma Trial in Zhengzhou, Shengyang, Hangzhou (HRS-3738)

Recruiting
  • Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
  • Zhengzhou, Henan, China
  • +2 more
Jul 27, 2022

Multiple Myeloma Trial in Wuhan (SENL103)

Recruiting
  • Multiple Myeloma
  • SENL103
  • Wuhan, Hubei, China
    Tongji Hospital
Sep 27, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Belantamab Mafodotin, Biospecimen

Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Belantamab Mafodotin
  • +6 more
  • Jacksonville, Florida
    Mayo Clinic in Florida
Apr 27, 2023

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Biospecimen Collection
  • +9 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 1, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (Actinium Ac 225-DOTA-Daratumumab, Daratumumab,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Actinium Ac 225-DOTA-Daratumumab
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix (Autologous MUC1-activated T-cells,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Phoenix, Arizona
    Mayo Clinic Hospital in Arizona
Jan 4, 2023

Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis Trial in Duarte (biological, drug, procedure, other)

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • +2 more
  • Daratumumab
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Nov 22, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Bortezomib, Metformin Hydrochloride,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
  • +1 more
Jan 5, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 24, 2023

Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Phoenix, Jacksonville, Rochester

Recruiting
  • Plasma Cell Myeloma
  • +3 more
  • Bone Marrow Biopsy
  • +3 more
  • Phoenix, Arizona
  • +2 more
Jan 18, 2023

The Aim is to Identify Recurrent Genomic Mutations and/or

Not yet recruiting
  • Multiple Myeloma
  • DNA sequencing
  • Pierre Benite, France
    Hospices Civils de Lyon
Apr 12, 2022

Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial in San Francisco (Pembrolizumab)

Not yet recruiting
  • Multiple Myeloma
  • +4 more
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Mar 23, 2022

Lymphoma, B-Cell, Leukemia, B-cell, Leukemia, T-Cell Trial in Cangzhou (CAR-T)

Recruiting
  • Lymphoma, B-Cell
  • +3 more
  • CAR-T
  • Cangzhou, Hebei, China
    Cangzhou People's Hospital
Nov 9, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Portland (Carfilzomib, Isatuximab, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jun 14, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Ann Arbor, Saint Louis (Dexamethasone, Ixazomib,

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
  • +3 more
Jan 6, 2023

Recurrent Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide)

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
Jan 4, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Buffalo, East Hills, West Islip (biological, drug, other)

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Abatacept
  • +3 more
  • Buffalo, New York
  • +2 more
Dec 22, 2022

Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Buffalo (behavioral, drug, other)

Recruiting
  • Plasma Cell Myeloma
  • +3 more
  • Behavioral Intervention
  • +6 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Jul 5, 2022

ISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma Trial in Atlanta

Active, not recruiting
  • ISS Stage I Plasma Cell Myeloma
  • +4 more
  • Pembrolizumab
  • Radiation Therapy
  • Atlanta, Georgia
    Emory University/Winship Cancer Institute
Mar 2, 2022

Anemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta, Columbus, Salt Lake City (drug, other,

Active, not recruiting
  • Anemia
  • +2 more
  • Atlanta, Georgia
  • +2 more
Jan 28, 2023

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Des Moines, Iowa
  • +8 more
Jan 12, 2023

Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma Trial in United States (ixazomib citrate, dexamethasone,

Active, not recruiting
Has Results
  • Refractory Plasma Cell Myeloma
  • Recurrent Plasma Cell Myeloma
  • ixazomib citrate
  • +2 more
  • Scottsdale, Arizona
  • +4 more
Mar 28, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Dexamethasone, Isatuximab)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022